NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million
Iovance Biotherapeutics (IOVA) announced revenue gains despite losses in its Q2 2025 results. On August 7, the company reiterated its product revenue guidance for 2025 within the $250 to $300 million range, driven by Amtagvi sales growth, and emphasized its positive outlook. Executive changes, including the appointment of Corleen Roche as CFO, brought additional expertise to the financial team. These developments coincided with a general market rally that saw major indices like the S&P 500...